Cargando…

Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease

BACKGROUND: The control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenk, Edeltraud J., Redekop, William K., Luyendijk, Marianne, Fitzpatrick, Christopher, Niessen, Louis, Stolk, Wilma A., Tediosi, Fabrizio, Rijnsburger, Adriana J., Bakker, Roel, Hontelez, Jan A. C., Richardus, Jan H., Jacobson, Julie, Le Rutte, Epke A., de Vlas, Sake J., Severens, Johan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849290/
https://www.ncbi.nlm.nih.gov/pubmed/29534061
http://dx.doi.org/10.1371/journal.pntd.0006250
_version_ 1783306024909799424
author Lenk, Edeltraud J.
Redekop, William K.
Luyendijk, Marianne
Fitzpatrick, Christopher
Niessen, Louis
Stolk, Wilma A.
Tediosi, Fabrizio
Rijnsburger, Adriana J.
Bakker, Roel
Hontelez, Jan A. C.
Richardus, Jan H.
Jacobson, Julie
Le Rutte, Epke A.
de Vlas, Sake J.
Severens, Johan L.
author_facet Lenk, Edeltraud J.
Redekop, William K.
Luyendijk, Marianne
Fitzpatrick, Christopher
Niessen, Louis
Stolk, Wilma A.
Tediosi, Fabrizio
Rijnsburger, Adriana J.
Bakker, Roel
Hontelez, Jan A. C.
Richardus, Jan H.
Jacobson, Julie
Le Rutte, Epke A.
de Vlas, Sake J.
Severens, Johan L.
author_sort Lenk, Edeltraud J.
collection PubMed
description BACKGROUND: The control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative and intensified disease management (IDM). METHODS: A systematic literature review identified information on productivity loss and out-of-pocket payments (OPPs) related to these NTDs, which were combined with projections of the number of people suffering from each NTD, country and year for 2011–2020 and 2021–2030. The ideal scenario in which the WHO’s 2020 targets are met was compared with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit equaled the difference between the two scenarios. Values are reported in 2005 US$, purchasing power parity-adjusted, discounted at 3% per annum from 2010. Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around the base-case impact estimate. RESULTS: The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 –I$ 34.0) billion in 2011–2020 and I$ 35.9 (I$ 25.0 –I$ 51.9) billion in 2021–2030 (2.5(th) and 97.5(th) percentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 –US$ 15.7) and US$ 16.6 billion (US$ 11.6 –US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods. CONCLUSIONS: We faced important limitations to our work, such as finding no OPPs for leprosy. We had to combine limited data from various sources, heterogeneous background, and of variable quality. Nevertheless, based on conservative assumptions and subsequent uncertainty analyses, we estimate that the benefits of achieving the targets are considerable. Under plausible scenarios, the economic benefits far exceed the necessary investments by endemic country governments and their development partners. Given the higher frequency of NTDs among the poorest households, these investments represent good value for money in the effort to improve well-being, distribute the world’s prosperity more equitably and reduce inequity.
format Online
Article
Text
id pubmed-5849290
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58492902018-03-23 Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease Lenk, Edeltraud J. Redekop, William K. Luyendijk, Marianne Fitzpatrick, Christopher Niessen, Louis Stolk, Wilma A. Tediosi, Fabrizio Rijnsburger, Adriana J. Bakker, Roel Hontelez, Jan A. C. Richardus, Jan H. Jacobson, Julie Le Rutte, Epke A. de Vlas, Sake J. Severens, Johan L. PLoS Negl Trop Dis Research Article BACKGROUND: The control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative and intensified disease management (IDM). METHODS: A systematic literature review identified information on productivity loss and out-of-pocket payments (OPPs) related to these NTDs, which were combined with projections of the number of people suffering from each NTD, country and year for 2011–2020 and 2021–2030. The ideal scenario in which the WHO’s 2020 targets are met was compared with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit equaled the difference between the two scenarios. Values are reported in 2005 US$, purchasing power parity-adjusted, discounted at 3% per annum from 2010. Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around the base-case impact estimate. RESULTS: The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 –I$ 34.0) billion in 2011–2020 and I$ 35.9 (I$ 25.0 –I$ 51.9) billion in 2021–2030 (2.5(th) and 97.5(th) percentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 –US$ 15.7) and US$ 16.6 billion (US$ 11.6 –US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods. CONCLUSIONS: We faced important limitations to our work, such as finding no OPPs for leprosy. We had to combine limited data from various sources, heterogeneous background, and of variable quality. Nevertheless, based on conservative assumptions and subsequent uncertainty analyses, we estimate that the benefits of achieving the targets are considerable. Under plausible scenarios, the economic benefits far exceed the necessary investments by endemic country governments and their development partners. Given the higher frequency of NTDs among the poorest households, these investments represent good value for money in the effort to improve well-being, distribute the world’s prosperity more equitably and reduce inequity. Public Library of Science 2018-03-13 /pmc/articles/PMC5849290/ /pubmed/29534061 http://dx.doi.org/10.1371/journal.pntd.0006250 Text en © 2018 Lenk et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lenk, Edeltraud J.
Redekop, William K.
Luyendijk, Marianne
Fitzpatrick, Christopher
Niessen, Louis
Stolk, Wilma A.
Tediosi, Fabrizio
Rijnsburger, Adriana J.
Bakker, Roel
Hontelez, Jan A. C.
Richardus, Jan H.
Jacobson, Julie
Le Rutte, Epke A.
de Vlas, Sake J.
Severens, Johan L.
Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease
title Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease
title_full Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease
title_fullStr Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease
title_full_unstemmed Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease
title_short Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease
title_sort socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: human african trypanosomiasis, leprosy, visceral leishmaniasis, chagas disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849290/
https://www.ncbi.nlm.nih.gov/pubmed/29534061
http://dx.doi.org/10.1371/journal.pntd.0006250
work_keys_str_mv AT lenkedeltraudj socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT redekopwilliamk socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT luyendijkmarianne socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT fitzpatrickchristopher socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT niessenlouis socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT stolkwilmaa socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT tediosifabrizio socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT rijnsburgeradrianaj socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT bakkerroel socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT hontelezjanac socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT richardusjanh socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT jacobsonjulie socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT lerutteepkea socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT devlassakej socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease
AT severensjohanl socioeconomicbenefittoindividualsofachieving2020targetsforfourneglectedtropicaldiseasescontrolledeliminatedbyinnovativeandintensifieddiseasemanagementhumanafricantrypanosomiasisleprosyvisceralleishmaniasischagasdisease